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40-Word Summary: CMV target sequence variation, amplicon size, and DNAse-
sensitive unprotected CMV DNA contribute to variability of viral load results and 
represent major obstacles for developing universally standardized and commutable 
CMV load thresholds for research and clinical practice. 
Twitter: Cytomegalovirus load quantification is affected by amplicon size and 
unprotected CMV genomes, not virions 
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Highlights 
 The Roche-CAP/CTM-CMV targeting UL54 under-quantified the CMV quality 
assurance UK-NEQAS-2014 
 In 329 CMV-UL54 targets, 43 mutations were identified, 8 being relevant in 
the UK-NEQAS-2014 
 New CMV-UL54-QNAT assays were designed of 361bp, 254bp, 151bp, and 
95bp amplicons 
 Smaller amplicon size increased quantification results causing 10-fold higher 
CMV loads 
 Plasma CMV loads in SOT patients reflect mostly unprotected genomes 
sensitive to DNase-I 
 
Abstract (250 words) 
Background Cytomegalovirus (CMV) management post-transplantation relies on 
quantification in blood, but inter-laboratory and inter-assay variability impairs 
commutability. An international multicenter study demonstrated that variability is 
mitigated by standardizing plasma volumes, automating DNA extraction and 
amplification, and calibration to the 1st-CMV-WHO-International-Standard as in the 
FDA-approved Roche-CAP/CTM-CMV. However, Roche-CAP/CTM-CMV showed 
under-quantification and false-negative results in a quality assurance program (UK-
NEQAS-2014).  
Objectives To evaluate factors contributing to quantification variability of CMV viral 
load and to develop optimized CMV-UL54-QNAT. 
Study design The UL54 target of the UK-NEQAS-2014 variant was sequenced and 
compared to 329 available CMV Genbank sequences. Four Basel-CMV-UL54-QNAT 
assays of 361bp, 254bp, 151bp, and 95bp amplicons were developed that only differed 
in reverse primer positions. The assays were validated using plasmid dilutions, UK-












samples from transplant patients submitted for CMV QNAT, with and without DNase-
digestion prior to nucleic acid extraction. 
Results Eight of 43 mutations were identified as relevant in the UK-NEQAS-2014 
target. All Basel-CMV-UL54 QNATs quantified the UK-NEQAS-2014 but revealed 10-
fold increasing CMV loads as amplicon size decreased. The inverse correlation of 
amplicon size and viral loads was confirmed using 1st-WHO-International-standard and 
patient samples. DNase pre-treatment reduced plasma CMV loads by >90% indicating 
the presence of unprotected CMV genomic DNA. 
Conclusions Sequence variability, amplicon length, and non-encapsidated genomes 
obstruct standardization and commutability of CMV loads needed to develop 
thresholds for clinical research and management. Besides regular sequence surveys, 
matrix and extraction standardization, we propose developing reference calibrators 
using 100bp amplicons. 
 




















1. Background (318 words) 
Cytomegalovirus represents a persisting challenge to transplant patients due to its 
direct and indirect effects decreasing graft and patient survival 1-4. Significant progress 
has been made in the clinical management of CMV replication post-transplantation 
through the concerted action of stratifying CMV risk according to CMV IgG serostatus 
of donor and recipient pairs, implementing prophylactic or preemptive antiviral 
strategies, and developing consensus definitions and guidelines 5-7. Central to current 
medical practice is the sensitive and specific detection and quantification of CMV 
replication for clinical studies as well as for therapy decisions 7, 8. Despite known 
limitations, this is widely approached by determining CMV DNA loads in blood using 
quantitative nucleic acid testing (QNAT)9-11. Although CMV QNAT is now clinically 
available with turn-around times of less than 6 hours, results from quality assurance 
programs and dedicated multicenter studies indicated that the CMV DNA load results 
may be highly variable across different centers and across different laboratory-
developed and commercial assays 12-14. Normalization to an external reference sample 
was shown to significantly reduce the spread of the reported viral load results, thus 
providing an important rationale for developing commutable calibrators such as the 1st 
WHO-approved CMV International Standard (1st-WHO-IS-CMV) 15-17. Indeed, an 
international multicenter study demonstrated previously that CMV load variability is 
mitigated across all participating laboratories when all steps and variables of the 
procedure were standardized such as using defined plasma volumes, automated DNA 
extraction and target amplification, and integrating calibration to 1st-WHO-IS-CMV as 
in the FDA-approved COBAS AmpliPrep/COBAS TaqMan CMV (in short: Roche-
CAP/CTM-CMV) 18. Despite an excellent performance record in our laboratories since 
its routine introduction 19, the Roche-CAP/CTM-CMV showed under-quantification and 
false-negative results of two quality assurance samples providing the same viral 












3521; specimen 2194 and 2195) 20. This observation elicited considerable uncertainty 
about the cause and the impact on clinical management, in several transplant centers 
including ours.  
 
2. Objectives (149 words) 
To determine the reasons for the Roche-CAP/CTM-CMV to fail the UK-NEQAS-2014 
distribution 3521, we hypothesized that sequence variations in the CMV-UL54 target 
region were responsible. Since the manufacture declined to provide this information or 
to reveal the target region, we identified two publications through a literature search 21, 
22, which suggested the presumed target region of the Roche-CAP/CTM-CMV to reside 
in the CMV UL54 DNA polymerase gene. We determined the sequence in the 
presumed UL54 target of the Roche-CAP/CTM-CMV resulting in quantification failure 
and compared the results to 329 available CMV GenBank sequences. We developed 
four new in-house CMV-UL54 QNAT assays designed to accommodate UL54 
sequence variations but differing in amplicon length. The assays were validated using 
reference and variant plasmid dilutions, 1st-WHO-IS-CMV, UK-NEQAS-2014 sample, 
as well as 107 frozen and 69 prospectively collected plasma samples submitted for 
CMV load, with and without DNase-digestion prior to nucleic acid extraction.  
 
3. Study design (669 words) 
3.1 Primers, probes, and plasmids 
Primers and probes used for amplification, QNAT and sequencing are indicated in 
Table 1. Plasmids harboring the presumed target sequence of CMV-strain AD169 and 
the UK-NEQAS-2014 sequence were chemically synthesized into the pUC57 plasmid 
(Eurogentec, Belgium) as denoted pCMV-AD169-UL54 and pCMV-UKNEQAS2014-
UL54. 
  












176 plasma samples tested for CMV load quantification were available from kidney 
and liver transplant patients consisting of 107 frozen samples for a retrospective study, 
and 69 prospectively collected samples. In 111 cases (49 retrospective; 62 
prospective), CMV loads were in the linear range of the Roche assay, above the lower 
limit of quantification (LLOQ 150 copies/mL; 137 IU/mL) in 50 cases (all retrospective) 
below the limit of detection (LOD 91 IU/mL) of the CAP/CTM-CMV assay 23, and in 15 
cases (8 retrospective; 7 prospective) above the LOD of 91 IU/mL, but below LLOQ of 
137 IU/mL (detected, but not quantifiable).  
 
3.3. DNase I digestion 
Samples above the LLOQ of the Roche assay were compared with and without DNAse 
digestion prior to extraction. DNase digestion was performed with 1 µL of 
Deoxyribonuclease I (238 U/µL; Invitrogen, USA) and 4.5 µL of 1 M MgCl (Ambion, 
USA) per 200 µL sample volume at 37°C for 30 minutes with subsequently added 11.1 
µL 0.5M EDTA (Invitrogen, USA). As DNase digestion control, normal human plasma 
spiked with 106 copies of pCMV-AD169-UL54 was run in parallel and then submitted 
to automated extraction. 
 
3.4. Extraction and quantitative nucleic acid testing (QNAT) 
Patient plasma and quality assurance samples were processed for the Roche-
CAP/CTM-CMV assay as described by the manufacturer (Roche, Rothkreuz; 
Switzerland; see above). For in-house measurements, 200 µL of plasma without and 
with prior DNAse I digestion, reconstituted UK-NEQAS-2014 sample, and 1st-WHO-IS-
CMV was used for extraction by the MagNA Pure 96 System (Roche, Switzerland) and 
eluted in 100 µL. The novel Basel-CMV-UL54-assays were performed with an ABI7500 
Fast Real-Time PCR System (Thermo Fisher Scientific, USA) using a reaction volume 
of 25 µL and 5 µL of extracted nucleic acids. QNAT was carried out with the qPCR 












(Eurogentec, Belgium), 300 nmoles end concentration of the forward primer Basel-
CMV-UL54_80134_F for -95bp, -151bp and -254bp, or 600nmoles for the -361 assay, 
100 nmoles of Basel-CMV-UL54_80203_80174_P for the -95bp, 200 nmoles for -
151bp, or 300 nmoles for -254bp and -361bp assay, and 300 nmoles of the indicated 
reverse primers, Basel-CMV-UL54-254_80387_R, Basel-CMV-UL54-151_80284_R or 
Basel-CMV-UL54-95_80228_R, or 600 nmoles of Basel-CMV-UL54-361_80494_R 
(Eurogentec, Belgium). The denaturation and cycling conditions were as follows:  50°C 
for 2 min for uracil-N-glycosylase (UNG) activation; 95°C for 10min to inactivate UNG 
and activation of HotGoldStar polymerase; 45 cycles of 95°C for 30s and 60°C for 90s 
for annealing and extension. The threshold of 0.02 was used for all Basel assays. The 
Basel-CMV-UL111a-77bp targeting another genome sequence UL111a has been 
described previously 18, 24. 
 
3.5. Sequencing 
The UK-NEQAS-2014 sample with the higher CMV loads was used for sequencing 
(specimen 2194). Briefly, following PCR using primers Basel-CMV-UL54_80133_F 
and Basel-CMV-UL54_80500_R (Table 1) and verifying PCR products on a 1% 
agarose gel, the amplicons were purified using Illustra ExoProStar 1-Step (GE 
Healthcare, England). The sequencing reaction was performed using the BigDye 
Terminator v3.1 cycle sequencing kit (Thermo Fisher Scientific, MA, USA), purification 
Sephadex G-50 Superfine (GE Healthcare, England) and sequencing by capillary 
electrophoresis on a 3500 Genetic Analyzer (Thermo Fisher Scientific, MA, USA). The 
sequences were analysed using the CodonCode Aligner (MA, USA) and then 
submitted to basic local alignment search tool (BLAST) analysis 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi). 
 












A sensitivity analysis was done by limiting dilution using the indicated plasmids at 106; 
104, and 102 copies per reaction, followed by two sets of 5-fold replicates of 2-fold 
dilutions starting from 100 copies/reaction down to 0.39 copies/reaction as described 
previously 25. The results of the Roche-CAP/CTM-CMV and the corresponding Basel-
CMV-UL54 assays were compared by linear regression and Bland-Altman analysis as 
described previously 25, 26. Statistical analysis was performed using ANOVA for multiple 





3. Results (1005 words) 
Primers Basel-CMV-UL54_80133_F and Basel-CMV-UL54_80500_R (Table 1) were 
designed to amplify and sequence the presumed UL54 target region in the CMV-
AD169 reference strain and in the UK-NEQAS-2014 (distribution no. 3521) sample. 
The corresponding 368bp-long amplicons were sequenced and analyzed using BLAST 
alignment. The UK-NEQAS-2014 sequence was compared with all 329 CMV 
sequences available in the NCBI GenBank database and phylogenetic analysis was 
performed using BLAST tree view (Fig. 1). The alignment identified a total of 43 
nucleotide deviations in the presumed UL54 target region (Fig. 1B; suppl. Table 1). 
The alignment also revealed that the UK-NEQAS-2014 distribution no. 3521 sample 
had been uploaded in the meantime under the acc. no. KJ361971 (Fig. 1). 
 
Since no relevant variations were found in the sequence targeted by the forward primer, 
Basel-CMV-UL54_80134_F was combined with different reverse primers, which were 
either specific for CMV-AD169 or the UK-NEQAS-2014 sequence, using the option of 
degenerate bases to accommodate the sequence variations (Basel-CMV-UL54-













95_80228_R; Table 1). Thereby, four different amplicons were generated of 361bp, 
254bp, 151bp, and 95bp, respectively (Fig. 2A). For detection, the probe targeted a 
sequence region close to the forward primer, which had no relevant base variations 
and which could be used to assay the generation of all four amplicons (Basel-CMV-
UL54_80203_80174_P, Table 1). To evaluate the impact of the sequence differences, 
reverse primers harboring degenerate bases were compared with specific primers for 
the CMV-AD169 and for UK-NEQAS-2014 sequences using 10’000 copies/reaction of 
the respective plasmids pCMV-AD169-UL54 and pCMV-UKNEQAS2014-UL54 (Fig. 
2B). The results revealed that the degenerate primer Basel-CMV-UL54-361_80494_R 
detected both targets equally well, whereas the other reverse primers having a 
mismatch only at the last position of the 3’ end (but degenerate bases at the other 
positions) failed to quantify the mismatched plasmid target by approximately 100-fold. 
Thus, the sequence variations were sufficient to explain the impaired CMV DNA 
quantification of the UK-NEQAS-2014 variant, which could be overcome by 
degenerate bases at the indicated positions. 
 
To evaluate the performance of the new Basel-CMV-UL54 assays, defined copy 
numbers of pCMV-AD169-UL54 of 106, 104 and 102 were compared. The amplification 
efficiency differed slightly showing slopes of -3.8 for the 95bp amplicon, -3.9 for the 
151bp amplicon, -4.3 for the 254bp amplicon, and -4.1 for the 361bp amplicon, all 
having correlation coefficients above 0.971. However, we noted that the novel Basel-
CMV-UL54 assays differed in Ct values for the same plasmid copy number (Fig. 3A). 
Thus, the Basel-CMV-UL54-95bp consistently required less amplification cycles for 
than any of the other Basel-CMV-UL54 having longer amplicons. Review of potential 













Next, we evaluated the novel Basel assays using the 1st-WHO-IS-CMV, which was 
diluted into negative human plasma (e.g. 10000 IU in 1 ml plasma) and extracted to 
contain the calculated international unit (IU) values over 4 orders of magnitude per 
reaction as indicated (10000 IU, 100 IU, 1 IU; Fig. 3B). The results also confirmed the 
inverse correlation of amplicon size and Ct values for this relevant calibrator. Moreover, 
the assays generating larger amplicons failed to detect CMV genomes at the lowest 
value of 1 IU/reaction. Finally, the quality assurance sample UK-NEQAS-2014 was re-
analyzed using all available CMV assays including the previously described Basel-
CMV-UL111a-77bp assay having an amplicon length of 77bp, but in a different CMV 
genome target, namely UL111a 24. Both, the Basel-CMV-UL54-95bp (p=0.05) and 
Basel-CMV-UL111a-77bp (p<0.05) showed higher viral loads compared to the 
intended results of this QA probe (Fig. 3C), whereas the Roche-CAP/CTM-CMV failed 
to quantify the CMV genome load. Together, the data demonstrated that sequence 
variability and amplicon size contributed significantly to the variability of CMV DNA 
loads. 
 
To investigate the impact of the new assays on CMV loads in transplant patients, we 
retrospectively examined 107 cryopreserved plasma samples submitted for routine 
CMV load testing using the Roche assay: 50 were below the LOD and found to be 
positive in 8 cases with 100 copies/mL using the Basel-CMV-UL54-95bp assay. In 
another 8 samples below LLOQ, but above LOD in the Roche assay, the Basel 
quantified 5 above 150 copies/mL. Finally, all of the 49 samples above LLOQ in the 
Roche assay had detectable CMV loads using the Basel-CMV-UL54-95bp, which were 
significantly higher as compared to the Roche-CAP/CTM-CMV results (Fig. 4A). 
Linear regression and Bland-Altman analyses revealed that this difference amounted 
to 0.6 log10 copies/mL on average across a range of CMV loads (Fig. 4BC). To 
investigate the contribution of unprotected CMV genome fragments, Basel-CMV-












acid extraction. The results revealed that 35 of 49 (71.4%) samples became 
undetectable, and that the CMV loads were significantly decreased for the remaining 
14 (28.6%) samples (p<0.05) (Fig. 4D).  
 
Since freezing and thawing of the plasma samples might affect these results, the 
Roche-CAP/CTM-CMV and the new Basel-UL54-CMV-95bp; - 254bp, and -361bp 
were prospectively compared in 69 plasma samples submitted for CMV load testing. 
Seven samples had CMV loads below the LLOQ of the Roche assay, but could be 
quantified by the Basel-UL54-CMV-95bp assay in 6 cases. For the larger amplicons of 
-254bp and -361bp, the number decreased to 5 and 3, respectively. Comparing the 
CMV loads, the results demonstrated that Basel-UL54-CMV-95bp yielded higher CMV 
loads including 6 of 7 samples, for which the Roche-CAP/CTM-CMV results had been 
below LLOQ (Fig. 5A). Linear regression and Bland-Altman analysis indicated higher 
CMV loads in the Basel-UL54-CMV-95bp across a range of CMV loads (average -1.08 
log10 copies/mL; Fig. 5B, top panel). The 10-fold higher CMV loads of the Basel-CMV-
UL54-95bp to the Roche-CAP/CTM-CMV disappeared for the assays having the 
254bp- and 361bp-amplicons showing values of -0.23 and 0.33 log10 copies/mL, 
respectively (Fig. 5B, middle and lower panel).  
Finally, DNase-I treatment of the prospectively collected plasma samples before 
nucleic acid extraction similarly revealed loss in CMV DNA detection in 42 of 68 
samples (61.8%), and a significant decline in CMV loads in the remaining 26 samples 
(38.2%) for Basel-UL54-CMV-95bp (Fig. 5C). For Basel-UL54-CMV-254bp and -
361bp, similar results were obtained. The results indicated that large parts of plasma 
CMV genomes were not protected suggesting that naked CMV DNA fragments 
significantly contributed to patient plasma CMV loads.  
 












The sensitive and specific quantification of CMV replication in peripheral blood is a 
cornerstone of current clinical management and key to clinical studies 9, 10. Although 
the 1st-WHO-CMV-IS as potentially commutable calibrator has improved result 
comparability across different laboratories 16, 27, a general agreement and definition of 
clinically relevant cut-offs is subject of current investigations 17. The current study 
demonstrates that standardization of CMV QNAT is challenged by sequence variability, 
amplicon length, and non-encapsidated CMV genome fragments, which alone or in 
combination represent significant obstacles to commutability of blood CMV loads.  
 
As shown here, these challenges arise on several, partly conceptual levels and cannot 
be solved by solely relying on commercial assay development. In fact, the failure of a 
well-validated commercial assay, that had been reported by Hirsch et al 2013 18 to 
mitigate differences between different laboratory through standardized matrix and 
volumes, automated extraction and amplification, came about through simple 
sequence variability in the assay target. We demonstrate here that sequence 
variations can be technically handled, but even though 329 CMV genome sequences 
were interrogated to provide a more robust choice of primers and probes, this can only 
be considered the latest state of knowledge, hence remaining error-prone, as more 
sequence information becomes available. Thus, regular review of sequence variation 
in the diagnostic target needs to be performed with corresponding updates of the assay 
chemistry. It remains to be debated if that can be achieved more reliably by diagnostic 
vendors interested in balancing cost -  benefit and approval by medical agencies, or 
by dedicated and accredited clinical virology laboratories. Clearly, QA programs may 
help to identify some of these issues. 
 
Second, the amplicon length emerged as an important variable in QNAT determined 
CMV load. Although initially driven by the desire to identify a more robust, hence 












same target DNA load were inversely correlated to amplicon length. This observation 
was made for plasmid targets, an international calibrator, as well as for patient plasma. 
The impact of amplicon length was more pronounced for low target copy numbers, 
where more rounds of enzymatic duplication were required suggesting a cumulative 
effect of the lower efficiency. This effect led to substantial under-quantification and 
even false-negative results in the Roche CAP/CTM-CMV as compared to the novel 
Basel assays. The differences in Ct values between the indicated Basel assays using 
plasmid or WHO dilutions were most pronounced, when using the -95bp assay as 
comparator (Fig.3). Comparison with our previously established Basel-CMV-UL111a-
77bp, which is based on 77bp amplicon, revealed only little difference to the Basel-
CMV-UL54-95bp, but an about a 10-fold difference to the Basel-CMV-UL54-361bp 
assay, that has the same amplicon length as the presumed Roche-CAP/CTM-CMV. 
Indeed, this difference between the Basel-CMV-UL111a-77bp and the Roche-
CAP/CTM-CMV has been observed previously in the multicenter study by Hirsch et al. 
in Fig.3 (site 4) 18, but was not yet understood in this way. Together, the data 
independently strengthen the role of amplicon size across different CMV gene targets. 
 
Notably, as this work was in progress, a seminal study of six North-American centers 
using serial dilutions of the 1st-WHO-CMV-IS and 40 plasma samples from patients 
indicated that the median inter-laboratory variation of CMV DNA loads remained in the 
order of 10-fold 17. Also in that study, amplicon length appeared to be the most 
important determinant across different commercial and laboratory-developed CMV 
QNAT assays. Moreover, Preiksaitis and colleagues demonstrated that large parts of 
the plasma CMV loads were fragmented and susceptible to DNase digestion 
suggesting the presence of non-encapsidated CMV genome fragments 28. These 
results are of utmost importance as they change the hitherto uncritical extrapolation 












infections virions to quantification of plasma CMV loads, which detects partly 
unprotected CMV DNA from virus replication and cell lysis elsewhere in the body 29, 30.  
Our results are in line with this observation in retrospectively and prospectively studied 
plasma samples reducing CMV loads both qualitatively (by 82% and 76%, 
respectively), as well as quantitatively.  
 
Thus, the presence of unprotected CMV genomic fragments may potentially limit the 
value of retrospective studies on frozen samples, especially when using large 
amplicons that intrinsically underestimate patient viral loads. In how far this affects the 
strategy of dual-target assays advocated by some centers 31 is presently little studied 
24, but given the goal of defining relevant cut-offs in blood or BAL 32, 33, dual detection 
leading to at least 2-fold differences may have an impact on management decisions.  
Finally, differences in viral loads attributable to viral DNA fragmentation may become 
less apparent if intact plasmid targets or virion genomes are used. The approach of 
defining international units by using mixed or heterogeneous preparations and simply 
averaging the quantification results of so-called reference laboratories that apply 
differently sized amplicons in commercial or laboratory-developed assays becomes 
questionable 34. Since the results are likely to affect other DNA viruses as well, and 
since internationally commutable calibrators for viral load determination are key to 
progress in clinical research and management, the question arises how to best achieve 
this goal. Given the constraints on primer and probe design arising from sequence 
variability, GC-content, primer dimers, secondary structure, and melting temperatures, 
it may be reasonable to develop generic baseline calibrators of 100bp in size, which 
could be referenced against probit and digital droplet analyses. 
 
In summary, our data together with the results of other researchers indicate that CMV 
sequence variability, amplicon size, and unprotected fragmented CMV DNA are 












sample matrix, volume, concentration and extraction procedure, we propose to 
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Figure 1: Phylogenetic analysis of CMV-AD169 strain and the UK-NEQAS-2014 
CMV sequences.  
A. Phylogenetic tree showing the relationship between the complete genomes of all 
261 HCMV (taxid 10359) GenBank sequences. The AD169 reference strain (acc. no. 
X17403) and the UK-NEQAS-2014 sequence (acc. no. KJ361971) are marked in red, 
UK-NEQAS-2014 is additionally highlighted in yellow and the blue line connects these 
two sequences that differ at 1263 (2%) nucleotide positions. Neighbor-joining method 
was used to analyze the sequences found by BLAST alignment using NCBI Blast Tree 
Viewer. Root indicates ultimate common ancestor, internal nodes the putative 
ancestors and leaves, viral sequences.  
B. Phylogenetic tree showing the relationship between the CMV-UL54 target sequence 
of all 329 HCMV (taxid 10359) GenBank sequences. The AD169 reference strain and 
UK-NEQAS-2014 are marked in red, UK-NEQAS-2014 additionally highlighted in 
yellow and the green line connects these two sequences that differ at eight nucleotide 
positions.  
 
Figure 2: Sequence, position, and quantification results of Basel-CMV-UL54 
target sequence, primers, and probe. 
A. Red squares in the upper panel and red letters in the lower panel indicate 
mismatches between the AD169 reference strain and the UK-NEQAS-2014 sample. 
The presumed CAP/CTM-CMV target is highlighted in light grey. Same forward primer 
(yellow) and probe (grey) were used for all four Basel QNATs, reverse primers are 
marked in purple for Basel-CMV-UL54-361bp, turquoise for Basel-CMV-UL54-254bp, 












Dotted line indicates presumed CAP/CTM-CMV primer that in contrast to the Basel-
CMV-UL54-361bp reverse primer, presumably has a G-to-A mismatch with UK-
NEQAS-2014 at the 3’ position.  
B. Influence of reverse primer and target sequence on quantification. The indicated 
copy numbers of the plasmids pCMV-AD169-UL54 and pCMV-UKNEQAS2014-UL54 
quantified with reverse primers ending with a mismatch at the 3’ end. Primer 
sequences are listed in Table 1. 
 
Figure 3: New Basel-CMV-UL54 qPCRs. 
A. Ct values of 106, 104 and 102 intact plasmid pCMV-AD169-UL54 target copies per 
reaction, determined by the four Basel-CMV-UL54 qPCRs.  
B. Ct values of intended 104, 102 and 100 IU per reaction (pre-extraction) of the 1st 
WHO HCMV International Standard (1st-WHO-IS-CMV, NIBSC 09/162, Merlin strain, 
acc. no. AY446894), determined by the four Basel-CMV-UL54 qPCRs. The hatched 












C. Viral load (log10 copies/mL) of UK-NEQAS-2014 sample (no.2195) that was 
detected, but not quantifiable using the Roche CAP/CTM-CMV assay. Mean of 
independent triplicates with standard deviation is indicated for each bar. The red star 
indicates the result of the Roche assay being detectable below LLOQ. 
 
Figure 4: Comparison of new Basel-CMV-UL54-95 qPCR to CAP/CTM-CMV assay 
by retrospective analysis. 
A. Viral loads (log10 copies/mL) of patient samples determined by the Roche-
CAP/CTM-CMV assay and retrospectively by the Basel-CMV-UL54-95bp QNAT 
(median, 25th and 75th percentile).  
B. Agreement plot with dashed line indicating 100% agreement level, linear correlation 
between Roche-CAP/CTM-CMV and Basel-CMV-UL54-95bp results with 95% 
confidence interval (CI) and Spearman’s correlation coefficient.  
C. Bland-Altman plot of Roche-CAP/CTM-CMV compared to Basel-CMV-UL54-95bp. 
The mean bias was -0.60, and the 95% limit of agreement between -1.19 and 0.00.  












Figure 5: Comparison of the Basel-CMV-UL54 qPCRs to CAP/CTM-CMV assay 
by prospective analysis. 
A. Viral loads (log10 copies/mL) of patient samples determined prospectively by the 
Roche-CAP/CTM-CMV assay and three of the new Basel-CMV-UL54 QNATs (median, 
25th and 75th percentile).  
B. Agreement plots (left panels) with dashed line indicating 100% agreement level, 
linear correlation between CAP/CTM-CMV and Basel-CMV-UL54 QNAT results with 
95% confidence interval (CI) and Spearman’s correlation coefficient. Bland-Altman 
plots (right panels) of CAP/CTM-CMV compared to each of the three Basel-CMV-UL54 
assays.  
C. Viral loads determined by the three QNATs Basel-CMV-UL54-361bp, -254bp, and 























Table 1  
Primer and probe sequences of the four Basel-CMV-UL54 and the Basel-CMV-UL111 qPCRs and their positions in 
the AD169 reference genome (acc. no. X17403).  
        
Primer / Probe  Sequence 5’-3’a  Position 
(acc.no.X17403) 
        
Basel-CMV-UL54 qPCRs       
     
Basel-CMV-UL54_80134_F  CCT ATC RGY GTC GCT G  80134-80149 
Basel-CMV-UL54-95_80228_R  GTT TCT TCG GGG CYA CAG  80228-80211 
Basel-CMV-UL54-151_80284_R  CGA AAA CGT GTC GCC  80284-80270 
Basel-CMV-UL54-254_80387_R  TTT GGC CGT GTC CTT GG  80387-80371 
Basel-CMV-UL54-361_80494_R  GCG AGG YKT YAT GTT CG  80494-80478 
Basel-CMV-UL54-
360_80493_GAC_R 
 CGA GGY KTY ATG TTC GAC  80493-80476 
Basel-CMV-UL54-
360_80493_GAT_R 
 CGA GGY KTY ATG TTC GAT  80493-80476 
Basel-CMV-UL54-
370_80503_GGT_R 
 GAT CGT GCC GCG AGG T  80503-80488 
Basel-CMV-UL54-
370_80503_GGC_R 
 GAT CGT GCC GCG AGG C  80503-80488 
Basel-CMV-UL54_80203_80174_P  6-FAM-CTA CAG TAT CTG CGT CAA CGT TTT CRG GCA-
BHQ-1 
 80203-80174 
        
Basel-CMV-UL54 PCR       
     
Basel-CMV-UL54_80133_F  GCC TAT CGG TGT CGC TGT   80133-80150 
Basel-CMV-UL54_80500_R  CGT GCC GCG AGG TGT CAT GT   80500-80481 
        
Basel-CMV-UL111a qPCR       













aDegenerate bases are indicated as follows: R, A and G; Y, T and C; K, T and G; BHQ, Black Hole Quencher; FAM, 6-carboxyfluorescein. 
 
Basel-CMV-UL111a-77_F  TTC ATC GAG TAA AAC CTA CGT TGG T  159835-159859 
Basel-CMV-UL111a-77_R  CCC GAC ACG CGG AAA A  159911-159896 
Basel-CMV-UL111a-77_P  6-FAM-CAA TAA ACC GTA CCT ACG TGA C-TAMRA  159883-159862 
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